

4. Armstrong MJ, Shulman LM, Vandigo J, Mullins CD. Patient engagement and shared decision-making: what do they look like in neurology practice? *Neurol Clin Pract* 2016;6:190–197.
5. Heesen C, Kasper J, Segal J, Kopke S, Muhlhauser I. Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis. *Mult Scler* 2004;10:643–650.
6. Kasper J, Kopke S, Muhlhauser I, Nubling M, Heesen C. Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial. *Eur J Neurol* 2008;15:1345–1352.
7. Poulos C, Kinter E, Yang JC, et al. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany. *Ther Adv Neurol Disord* 2016;9:95–104.
8. Utz KS, Hoog J, Wentrup A, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. *Ther Adv Neurol Disord* 2014;7:263–275.
9. Wilson LS, Loucks A, Gipson G, et al. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. *Int J MS Care* 2015;17:74–82.
10. Ng P, Murray S, Hayes SM. Clinical decision-making in multiple sclerosis: challenges reported internationally with emerging treatment complexity. *Mult Scler Relat Disord* 2015;4:320–328.
11. Saposnik G, Sempere AP, Prefasi D, et al. Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS). *Front Neurol* 2017;8:65.
12. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology* 2018;90:777–788.
13. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS registry: diagnosis. *Mult Scler* 2007;13:770–775.
14. Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. *Mult Scler* 2007;13:1176–1182.
15. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. *Neurology* 1999;52:63–70.
16. Gronseth GS, Woodroffe LM, Getchius TSD. Clinical Practice Guideline Process Manual. St. Paul, MN: American Academy of Neurology; 2011.
17. Rosato R, Testa S, Oggero A, Molinengo G, Bertolotto A. Quality of life and patient preferences: identification of subgroups of multiple sclerosis patients. *Qual Life Res* 2015;24:2173–2182.
18. US Food and Drug Administration. Guidance for industry: providing clinical evidence of effectiveness for human drugs and biological products. Available at: fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072008.pdf. Accessed May 19, 2017.
19. Office of the Auditor General of Canada. Regulating Pharmaceutical Drugs: Health Canada. Report of the Auditor General of Canada to the House of Commons [serial online]. 2011. Available at: publications.gc.ca/collections/collection_2012/bvg-oag/FA1-2011-2-4-eng.pdf. Accessed May 19, 2017.
20. European Commission. Health and Food Safety Directorate-general. Procedures for Marketing Authorisation: Marketing Authorization. Brussels: European Commission; 2016: 1–49.
21. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. *Neurology* 2004;63:1788–1795.
22. Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. *Neurology* 2002;59:679–687.
23. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. *Lancet* 2013;381:2167–2175.
24. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. *Med Decis Making* 2015;35:114–131.
25. Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. *Mult Scler* 2017;23:185–190.
26. Stacey D, Legare F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev* 2014;CD001431.
27. Elwyn G, Frosch DL, Kobrin S. Implementing shared decision-making: consider all the consequences. *Implement Sci* 2016;11:114.
28. The Guidelines International Network Public and Patient Involvement Working Group. G-I-N Public Toolkit: Patient and Public Involvement in Guidelines. 2015. Available at g-i-n.net/document-store/working-groups-documents/g-i-n-public-toolkit/toolkit-2015. Accessed May 19, 2017.

CORRECTION

Apathy and functional disability in behavioral variant frontotemporal dementia

Neurology: Clinical Practice June 2018 vol. 8 no. 3 185 doi:10.1212/CPJ.0000000000000475

In the article “Apathy and functional disability in behavioral variant frontotemporal dementia” by M.S. Yassuda et al.,¹ there is an error in the seventh author’s name, which should have read “Viviane Amaral-Carvalho” rather than “Viviane Almaral-Carvalho” as originally published. The authors regret the error.

Reference

1. Yassuda MS, Lima da Silva TB, O’Connor CM, et al. Apathy and functional disability in behavioral variant frontotemporal dementia. *Neurol Clin Pract* 2018;8:120–128.

Neurology® Clinical Practice

Apathy and functional disability in behavioral variant frontotemporal dementia

Neurol Clin Pract 2018;8;185

DOI 10.1212/CPJ.0000000000000475

This information is current as of June 11, 2018

Updated Information & Services	including high resolution figures, can be found at: http://cp.neurology.org/content/8/3/185.full.html
References	This article cites 1 articles, 1 of which you can access for free at: http://cp.neurology.org/content/8/3/185.full.html#ref-list-1
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://cp.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://cp.neurology.org/misc/addir.xhtml#reprintsus

Neurol Clin Pract is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright © 2018 American Academy of Neurology. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.

